<DOC>
	<DOCNO>NCT01075607</DOCNO>
	<brief_summary>The objective study identify validate metastasis protein marker lymph collect woman metastatic breast cancer . We examine peripheral blood presence identify marker order develop user friendly clinical test detect metastasis evaluate response therapy .</brief_summary>
	<brief_title>Lymph Fluid Blood Collection Identification Novel Biomarkers</brief_title>
	<detailed_description>The goal study identify node-negative breast cancer patient unlikely benefit adjuvant chemotherapy , thus save adverse effect unnecessary treatment . We propose identify validate protein marker determine breast cancer recurrence metastasis , base approach group recently find highly promising biomarker discovery . The objective research identify validate metastasis protein marker lymph collect vessel exit primary tumor prior entry sentinel lymph node woman metastatic breast cancer . Realizing novel procedure adopt routine clinical use , examine peripheral blood presence identify marker order develop user friendly clinical test detect metastasis evaluate response therapy .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women , age great equal 18 , histologically and/or cytologically confirm diagnosis adenocarcinoma breast metastatic ( node positive ) and/or nonmetastatic ( node negative ) breast cancer . No prior chemotherapy treatment . Women , age great equal 18 , carcinoma situ opt mastectomy . Able provide inform consent HIPAA authorization . Hormone therapy past six month . Birth control pill use allow . History radiation therapy chest . Previous current use aromatase inhibitor ( AI ) Selective Estrogen Receptor Modulator ( SERM ) medication . History chemotherapy breast cancer . Pregnant breastfeeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Lymph fluid collection</keyword>
</DOC>